Century Therapeutics Inc. Common Stock (IPSC)

FairStock Score: 64/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Century Therapeutics as a pre-profit biotech, not a compounding business. It is developing allogeneic cell therapies, with CNTY-813 for type 1 diabetes and CNTY-308 in oncology. In fiscal 2025, the year ended 2025-12-31, revenue was $109.2M and net income was -$9.6M, or diluted EPS -$0.14. That was a sharp swing from fiscal 2024, when revenue was $6.6M and net loss was $126.6M, and fiscal 2023, when revenue was $2.2M and net loss was $136.7M. But the improvement did not persist: in fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $21.6M, or -$0.11 per diluted share, and in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $34.5M, or -$0.17 per diluted share. TTM free cash flow is -$88.1M, a -35.3% FCF yield on the $249.9M market cap at the 2026-10-13 close. FairStock calculations show P/E -1.48, P/B 1.07, ROE -49.65%, ROCE -23.51%, Piotroski 4/9, and Altman Z 0.30. FairStock assigns no Peter Lynch category because it has lost money in each of the last four years. Debt/equity is modest at 0.17, but cash burn, not leverage, is the risk. The price may look near accounting value, but without earnings or an approved product there is no margin of safety in Graham's sense. This is a clinical-news-driven speculation, not a business I can value on earnings. I would watch cash runway, trial data, partnerships, and whether revenue becomes recurring.

In plain English: Century Therapeutics is a small biotech company working on cell therapies for cancer, autoimmune disease, and type 1 diabetes. It lost money in each of the last several years and is still using cash, although revenue in the year ended 2025-12-31 was much higher than in the two prior years. At the 2026-10-13 close, its $1.38 share price and roughly $249.9 million market value leave it hard to call clearly cheap or expensive without profits, though the stock is near its accounting value and the business remains risky.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer